NEW YORK(GenomeWeb) – HealthTell said today that it has received a $225,000 SBIR grant from the National Institutes of Health.

The funds will support work to evaluate the effectiveness of the company's immunosignature technology in the diagnosis of brain cancer, and glioblastoma multiforme, specifically.

According to HealthTell, the company aims through the project to demonstrate its platform's ability to distinguish primary brain cancers from brain cancers arising as metastases from other sites; and to differentiate brain cancer subtypes and grades of malignant gliomas.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.

Aug
23
Sponsored by
Tecan

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.